Another negative study trying to add anti-PD1/L1 to RT or chemoRT in locally advanced head and neck cancer
Ezra Cohen, Chief Medical Officer of Oncology Tempus Labs, Inc., shared on LinkedIn:
“This is another negative study trying to add anti-PD1/L1 to RT or chemoRT in locally advanced head and neck cancer. Nonetheless, there are some important takeaways about the population enrolled. We can define eligibility and there is a clinical need to find therapies for platin-ineligible patients. Furthermore, we now have prospective PFS and OS data to work from. Perhaps neoadjuvant IO in a biomarker selected cohort should be the next trial.”
Authors: Pedro A Torres-Saavedra, Prof Stuart J Wong, Prof Julie A Kish, Steven S Chang, Prof Richard C Jordan, Tian Liu, Prof Minh Tam Truong, Prof Eric W Winquist, Vinita Takiar, Trisha Wise-Draper, Prof Jared R Robbins, Prof Cristina P Rodriguez, Musaddiq J Awan, Beth M Beadle, Christina Henson, Samir Narayan, Prof Sharon A Spencer, Steven Powell, Prof Neal Dunlap, Assuntina G Sacco, Prof Kenneth Shung Hu, Henry S Park, Prof Julie E Bauman, Jonathan Harris, Prof Sue S Yom, Quynh-Thu Le.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023